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THE theory that the neoplastic process occurs in distinct stages, now widely
accepted (see reviews: Furth, 1953; Anotation, Lancet, 1953), is based on
diverse clinical and experimental evidence. The experimental demonstration
of stages in the chemical induction of tumours in skin is largely due to the work
of Rous and of Berenbium and their respective colleagues (Rous and Kidd, 1941;
MacKenzie and Rous, 1941; Berenblum, 1941a, 1941b; Berenblum and Shubik,
1947a, 1947b).
Much is still unknown of the nature and limits of these stages, their relation
to one another, their powers ofpersistence, progression, or regression, and to what
extent they lie on one or on altemative pathways.
Various terminologies have been proposed for the stages of carcinogenesis,
which are not entirely equivalent, and there is increasing danger ofconfusion. We
propose to restrict ourselves to a few almost self-explanatory terms. By car-
cinogen we mean a substance capable of producing malignant tumours when
applied in adequate dose to a susceptible tissue. Bv incomplete carcinogen we
mean a substance which plays some part in tumour production but is incapable of
producing malignant tumours when applied alone. There are clearly several
kinds of incomplete carcinogen. Two kinds concern us in the present work:
initiating agents (Friedewald and Rous, 1944), namely substances capable of
causing a preneoplastic change (whether pre-benign or pre-malignant), and
promoting agents (Friedewald and Rous, 1944), often called co-carcinogens, capable
ofproducing tumours in tissue which has suffered the action ofan initiating agent.
Of these latter some, perhaps, may promote the development of both benign and
malignant tumours, and some that ofone but not the other. At present, however,
our knowledge is insufficient to make these distinctions.
A carcinogen must, of course, have both initiating and promoting properties,
though in certain doses or situations it may show only one of these. There are
substances, however, which are incomplete carcinogens underallknown conditions.
To bring about only the first, or preneoplastic, part of the change in skin--the
"initiating " process-it has hitherto been necessary to apply a small dose of a
carcinogen, insufficient to produce tumours by itself. That is to say, all hitherto
recognised initiating agents are potentially carcinogenic. The second part of
the change, the production of tumours, can be brought about either by further
applications of a carcinogen, or by various " promoting " agents which rarely,
ifever, produce tumours in untreated tissue. The most effective for mouse skin,
and the most studied, is croton oil.INCOMPLETE CARCINOGENS
The question whether the development of malignancv can be regarded as a
third part of the neoplastic process (Berenblum, 1941b), implying that it occurs
only after the completion of the first and second parts, is one which cannot be
answered at present. It has been stated that tumours arising in mouse skin
treated once with 9: 10-dimethyl-1 2-benzanthracene and then repeatedly with
croton oil are almost all benign (Shubik, 1950). Work in this laboratory, shortly
to be reported, has shown that this treatment does give rise to a considerable
number of malignant tumours
- they appear many months later than the benign
tuniours, and arise as often as not in sites where no benigntumours have previously
been seen. Further consideration of the malignant change will be deferred until
this work is completed.
The object ofthe present work was to test the hypothesis that there exist also
initiating agents which are not carcinogens, at any rate for the tissue under
treatment.
The substances chlosen for examination were either carcinogens for other
tissues or species but not for mouse skin, or mitotic poisons, or both.
MATERIALS AND METHODS.
Mice.--Stock albinos of the " S " strain (Salaman and Gwynn, 1951) fed on
cubes prepared according to the Rowett Institute formula (Thonison, 1930a,
1930b) plus fresh greenstuff twice a week, and water ad libitum.
In the second experiment all were vaccinated with sheep lymph on the tail,
and only positive reactors used. (This was a precaution against ectromelia.
Vaccination, even within the treated area, has been found in this laboratory to
be without appreciable effect on tumour production by 9: 10-dimethyl-1: 2-
benzanthracene, whether or not followed by croton oil.)
Chemical agents.-9: 10-Dimethyl-1: 2-benzanthracene (DMBA) and 2-acetyl-
aminofluorene (AAF) were obtained from Messrs. L. Light & Co; ethyl carbamate
(urethane) from British Drug Houses; p-dimethylaminoazobenzene (butter
yellow, BY) from Messrs. Hopkin & Williams; and methyl bis (fi-chloroethyl)
amine hydrochloride (nitrogen mustard, NM) from Messrs. Merck & Co. NN-
di(2-chloroethyl)-,/-naphthylamine (R48) was kindly presented by Professor
Boyland of the Chester Beatty Institute. Croton oil was obtained from Messrs.
Boots' Pure Drug Co. Acetone (analar grade of British Drug Houses) was used
as a solvent throughout.
Application of substances.-The hair of the whole back from forelimbs to tail
was clipped before treatment, and at intervals when necessary. The solutions
were delivered from calibrated pipettes, care being taken that they spread as
evenly as possible over the whole clipped area. 02 ml. volumes of the DMBA
solution and 0 3 ml. of all the others were used. When the required dose could
not be dissolved in 0.3 ml., two or three applications of 0 3 nil. were made with
sufficient interval to allow evaporation of the solvent (approximately 15 minutes).
Recording oftumours.-Mice were inspected once a week, and tumours of 1 mm.
diameter and over recorded.
Histological examination.-Biopsies of skin about 1 x 0 5 cm. were taken
from the treated areas under ether anaesthesia, on the days indicated below.
They were fixed in Zenker's fluid, and stained with haematoxylin and eosin-
Biebrich scarlet (Gwynn and Salaman, 1953).
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Mice dying of intercurrent infection, and those killed at the end of the first
experiment, were examined post mortem. Selected organs were taken for histo-
logical examination.
FIRST EXPERIMENT.
In a preliminary test, intended to fix conditions for a larger experiment,
fivesubstanceweretestedfor initiating power, in varying concentrationsinacetone.
68 female mice, 5-7 weeks old, were divided into groups and subgroups (the latter
of 4 mice each) and treated as follows:
Primary treatments.
Group 1. p-Dimethylaminoazobenzene (BY):
(a) 0-3 ml. 2 per cent solution (6 mg.).
(b) 0-3 ml. 4 per cent solution (12 mg.).
(c) 0*3 ml. 8 per cent solution (24 mg.).
Group 2. 2-Acetylaminofluorene (AAF).
(a) 0 3 ml. 2 per cent solution (6 mg.).
(b) 0-3 ml. saturated solution (approx. 10 mg.).
(c) 0 3 ml. saturated solution, 2 applications with an interval of 15
minutes (approx. 20 mg.).
Group 3. Ethylcarbamate (urethane):
(a) 0 3 ml. 20 per cent.w/v solution (60 mg.).
(b) 0-3 ml. 20 per cent w/v solution, 2 applications with an interval of
15 minutes (120 mg.).
(c) 0*3 ml. 20 per cent w/v solution, 3 applications with intervals of
15 minutes (180 mg.).
Group 4. Methyl bis (,fl-chloroethyl) amine hydrochloride (NM):
(a) 0-3 ml. 0-01 per cent solution (0 03 mg.).
(b) 0-3 ml. 0 033 per cent solution (0-1 mg.).
(c) 0 3 ml. 041 per cent solution (0 3 mg.).
(d) 0 3 ml. 0-2 per cent solution (0.6 mg.).
Group 5. NN-di(2 -chloroethyl)-,f-naphthylamine (R48):
(a) 0 3 ml. 041 per cent solution (0 3 mg.).
(b) 0 3 ml. 0 33 per cent solution (1 mg.).
(c) 0 3 ml. I 0 per cent solution (3 mg.).
(d) 0 3 ml. 2-0 per cent solution (6 mg.).
On the 3rd day biopsies of skin were taken from the treated areas for micro-
scopic examination. On the 7th day the above treatments were repeated. On
the 10th day a further series of biopsies were taken from the treated areas.
Secondary treatments.
Weekly applications of 0-3 ml. 0-5 per cent croton oil in acetone were begun
after intervals ofeither 28 or 49 days (in view ofBerenblum's and Shubik's results,
1947b, 1949, the length of this interval was not considered to be critical), and
continued for 20 weeks. The number of tumours was recorded weekly. They
were all of typically benign appearance (naked eye). A number of mice died of
intercurrent infection, and the remainder were sacrificed at 22-33 weeks. All
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were examined post mortem. As mentioned in the introduction, experience in
this laboratory has shown that malignant tumours develop only after longer
periods in this type of experiment.
Results.
Tumour incidence.
Table I shows the number of tumours on mice surviving 16 and 20 weeks of
croton oil treatment respectivelv.
TABLE I.-First Experiment.
Primary Treatment: Test substance, dissolved in acetone, applied
to skin of back on 2 successive weeks.
Interval: 4-7 weeks.
Secondary Treatment: 0 3 ml. 0*5 per cent croton oil in acetone applied
to treated areaweeklyfor20weeks.
Number of tumours/
surviving mice after
Number croton oil treat-
Group. of mice. Test substances. ment for:
o-A
16 weeks. 20 weeks.
1 . 12 . p-Dimethylaminoazobenzene (butter yellow, BY) . 1/8 0/3
12-48 mg.
2 . 12 . 2-Acetylaminofluorene (AAF) 12-40 mg. 0/12 0/4
3 . 12 . Ethyl carbamate (urethane) 120-360 mg. . 13/8 11/5
4 . 16 . NN-di (2-chloroethyl)-,j-naphthylamine (R48) 0-6 . 1/11 1/11
-12 mg.
5 . 16 . Methyl bis (A,-chloroethyl) amine hydrochloride . 0/14 6/14
(nitrogen mustard, NM) 0*06-1-2 mg.
Control* . 40 . None (croton oil controls) . 1/36 5/36
* From a previous experiment.
Prolonged treatment with croton oil alone gives rise to a few papillomas. In
a previous experiment 1 and 5 tumours were present on 36 mice treated in this
way at the 16th and 20th weeks repectively. The number of tumours which
appeared in Group 3 indicate that urethane had a definite initiating effect.
Tumours which appeared in the other groups may have been the result of the
croton oil treatment, but the 6 tumours on 14 mice in Group 5 suggest a possible
initiating action by NM.
Histological examination: (a) Biopsies of skin.
BY.-In mice treated with an 8 per cent solution slight epidermal hyperplasia
with a corresponding increased frequency of mitosis, but without abnormalities
of cellular size and arrangement or damage to hair follicles, was seen on the 3rd
day. By the 10th day the skin had returned to its normal appearance, except
for the presence of a slight excess of keratin.
AAF.-No significant changes were seen on the 3rd or 10th day.
Urethane.-No significant changes were seen on the 3rd or 10th day (Fig. 6).
NM.-In mice treated with a 0-2 per cent solution there was variable epidermal
hyperplasia on the 3rd dav, marked in 2 out of 4. By the 10th dav all the mice
showed gross hyperplasia of the epidermis, with definite irregularity of cellular
arrangement and variation in size and staining of cells and nuclei (Fig. 2 and 3).
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There was also destruction of many of the sebaceous glands, and reduction of
some of the follicles to epithelial pegs. I-n mice treated with 0.1 per cent NM
similar but less marked changes were seen.
R48.-In miice treated with a 2 per cent solution a hyperplasia ofthe epidermis
was seen, slight on the 3rd but definite on the 10th day. There was even greater
irregularity of cellular arrangement and size than in the NIM group. Many of
the epidermal cells were very large, with enormous pale-staining nuclei, and the
average cell size was well above normal. By the 10th day there was destruction
of many sebaceous glands (Fig. 4 and 5).
(b) Organ histology.-Post mortem examination of mice painted initially with
BY, AAF, NM, and R48 showed nothing of note.
Of the mice painted initially with urethane, 4 out of 9 which survived more
than 7 weeks showed multiple lung adenomata. These varied in size from 2 5 mm.
diameter down to those that could only be seen under the microscope. They were
mucus secreting, and generally fitted the description of Nettleship and Henshaw
(1943). In addition, one of these four mice had a large tumour replacing the
base ofthe right lung, adherent to the chest wall and leading to haemothorax and
death. Histologically this tumour was adenomatous and mucus secreting, but
itwasnotpossible to decidewhether it was asimpleadenoma oranadenocarcinoma
because of post-mortem changes.
On the completion of the first experiment another was set up in which all
the substances used in the first experiment were re-tested. for initiating power,
and also for promoting power after a single dose of a carcinogen, and for carcino-
genic action when applied alone. Much larger numbers of mice were used.
Unfortunately this experiment had to be abandoned owing to intercurrent infec-
tion before significant results were obtained. It was then decided, on the results
of the first experiment which had demonstrated unequivocally the initiating
power of urethane, to select this substance for further study, and to postpone
re-examination of the other substances.
SECOND EXPERIMENT.
A full scale examination of urethane for initiating power, with control tests
for promoting and carcinogenic action, was carried out. 170 male mice, 7-8
weeks old, which had been successfully vaccinated with sheep lymph on the tails,
were divided into 8 groups. Primary and secondary treatments in each group
are given in Table II.
Re8ults.
Tumour incidence.
The number oftumours produced in the survivors after 18 weeks ofsecondary
treatment are given in Table II, and the course oftumour development in Groups
7, 9, and 13 is illustrated in Fig. 1, in which numbers of tumours per surviving
mouse are plotted against time. These results may be summarised as follows.
No tumours were produced by:
0 3 mg. DMBA, with no further treatment;
03 mg. DMBA, followed by 18 weekly doses of 60 mg. urethane;
2 weekly doses of 120 mg. urethane, with no further treatment;
or 18 weekly doses of 60 mg. urethane.
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TABLE II.-Second Experiment.
Number
Group. of mice Primary treatment
6 . 20 . DMBA, 0-3 mg.
7 . 20 . DMBA, 0*3 mg.
8 . 20 . None
9 . 26 . Urethane, 240 mg. (120
mg. on 1st and 8th
days)
24
20
12 . 20
13 . 20
. Urethane, 240 mg. (as
in group 9)
DMBA, 0-3 mg.
None
None
Interval. Secondary treatment.
4 weeks . None
4 weeks . Croton oil, 0-3 ml. 0-5
per cent weekly for
18 weeks
Croton oil, as in group 7 .
4 weeks . Croton oil, as in group 7 .
from first
applica-
tion of
urethane
None
4 weeks . Urethane, 60 mg.
weekly for 18 weeks
Urethane, as in group
11
Croton oil, as in group
7, on Tuesdays;
Urethane, as in group
11, on Fridays
Acetone was the solvent throughout.
Large numbers of tumours were produced by:
2 weekly doses of 120 mg. urethane followed by weekly applications of
0-5 per cent croton oil;
alternate weekly applications of 60 mg. urethane and 0-5 per cent croton
oil;
or 0-3 mg. DMBA followed by weekly applications of 0-5 per cent croton
oil.
Croton oil applications alone produced very few tumours (3 in 20 mice after
18 weeks).
Histological appearances.
Examination ofbiopsies from 6 mice of Group 12, 6 days after the 18th weekly
application of urethane, showed no hyperplasia of the epidermis or other abnor-
mality (Fig. 7).
DISCUSSION
The results of these experiments have shown that urethane when applied to
mouse skin possesses peculiar properties. Like the carcinogenic hydrocarbons
it has the power of initiating the process of skin tumour formation. Unlike them
it produces no tumours when applied alone, in high doses or repeatedly. Unlike
croton oil it does not promote the formation of skin tumours after an initiating
dose of a carcinogen. It is, in fact, what we set out to find, namely, an initiating
agent but neither a carcinogen nor a promoting agent for mouse skin.
In considering the results obtained with the other substances tested in the
first experiment, it should be noted that repeated applications of0-5 per cent croton
10
11
Tumours/
surviving
mice after
18 weeks
secondary
treatment
0/20
104/18
3/20
115/22
0/19
0/15
0/17
138/17
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v(17survivors)
10 12 14 16 18 20 22
Time in weeks from beginning of primary treatment
24
FIG. 1.-Development of tumours in treated mice.
A - A Group 7(20mice): 0-3mg.DMBA onfirstday; 0-3ml.0*5per
cent croton oil weekly from 4th to 21st week.
x .x Group 9 (26 mice): 120 mg. urethane on first day; 120 mg.
urethane on eighth day; 0 3 ml. 0 5 per cent croton oil weekly from 4th to 21st week.
0 o Group 13 (20 mice): Alternate applications of 60 mg. urethane and
0(3 ml. 0 5 per cent croton oil every 3 to 4 days from 4th to 21st week. (No previous
treatment.)
oil in acetone produced a few tumours. The number of these has varied, in past
experiments, from 0 to 0-2 tumours per mouse after 20 weekly applications. It
is therefore probable that the occasional tumour seen in the BY aVd R48 groups
was produced by the croton oil. In the NM group, however, there were 6 tumours
EXPLANATION OF PLATES.
FIG. 2-8.-Dorsal mouse skin from treated areas. Fixed Zenker's fluid. Stained haematoxylin
and eosin-Biebrich scarlet. x 250.
FIG. 2.-3 days after application of 0 3 ml. 0-2 per cent nitrogen mustard in acetone.
FIG. 3.-3 days after 2nd weekly application of the same.
FIG. 4.-3 days after application of 0 3 ml. 2 per cent " R48".
FIG. 5.-3 days after 2nd weekly application of the same.
FIG. 6.-3 days after 2nd weekly application of 0 9 ml. 20 per cent urethane in acetone.
FIG. 7.-6 days after 18th weekly application of 0-3 ml. 20 per cent urethane in acetone.
FIG. 8.-3 days after application of 0-2 ml. 0-15 per cent 9: 10-dimethyl-1: 2-benzanthracene
in acetone.
Note that the epidermal hyperplasia in skin treated with NM, R.48, and DMBA is of the
same general type. Note also the absence of hyperplasia in skin treated with urethane.
For further description of these appearances see text.
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in 14 surviving mice after 20 weeks' treatment with croton oil, which suggested
that NM had some initiating power; but the number of mice was too small for a
definite conclusion to be drawn. A further test of this substance is planned.
It might be argued from the results of the second experiment that urethane
is a much weaker initiator than are carcinogens such as DMBA, since the dose of
the former was about 1,000 times that of the latter for comparable effect. Such
reasoning would not be justified. The dose of urethane given may have been
more than the optimum (cf. Shubik and Ritchie, 1953), and a smaller dose might
have proved equally or even more effective. This possibility is being investigated.
It is probable, however, that urethane, a very soluble and rapidly eliminated
drug, would need to be applied to the skin in much higher concentration, for
comparable effect, than the carcinogenic hydrocarbons which persist in the skin
for several days at least. In work of this kind the concentration of applied
substances is not by itself of much significance. The dose which reaches the site
ofaction in the tissue depends on many factors, ofwhich the applied concentration
is only one.
The choice of concentrations was actually based on several considerations.
The applied doses of R48 and NM were such as to produce slight but definite
epidermal hyperplasia-presumptive evidence that they had reached the suscep-
tible cells. Urethane was used in doses which caused transient narcosis, showing
that it had at least traversed the skin. Solubility in acetone was a limiting factor
in the cases of BY and AAF, but the doses given were considerably in excess of
those previously given by other routes. It is possible that the use of larger
doses might have revealed activity in some of the substances which appeared
inactive, but in the present work the primary object was to select substances with
easily demonstrable initiating action. The detection of minor degrees of activity
has been deferred.
The histological appearances ofskin after treatment with the various substances
were of considerable interest. AAF produced no detectable abnormality and
BY only a very slight epidermal hyperplasia, after 2 weekly applications. NM
and R48, however, produced after 3 and 10 days a type of epidermal hyperplasia
(Fig. 2, 3, 4, and 5) chiefly characterised by gross irregularity in size and arrange-
ment of cells, which, as Pullinger (1940) has shown, is typical of the effects of
carcinogenic as opposed to non-carcinogenic irritants. For comparison a section
ofmouse skin 3 days after a single application of 0.15 per cent DMBA in acetone is
shown (Fig. 8). Even after 18 weekly applications of urethane both naked-eye
and microscopic appearances of the skin were normal (Fig. 6). Thus wehave
the apparently anomalous result that two substances, in doses which produced
reactions in the skin typical of the early effects of carcinogens, were inactive (or,
in one case, perhaps slightly active) as initiators, while another substance which
gave no detectable skin reaction was an effective initiator.
The mice treated with urethane and croton oil have been under observation
for 7 months. So far the tumours which have arisen on the treated skin are all
benign in appearance. Only benign tumours are produced by a small dose of a
carcinogen followed by croton oil during the first 6 months or more (Shubik, 1950).
As mentioned above, experiments recently completed in this laboratory show
that in mouse skin given the latter type of treatment malignant tumours appear
at a later date, many of them without obvious relation to pre-existing benign
tumours. It is quite possible that malignant tumours will still appear in the mice
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tteated with urethane and croton oil, which are still under observation.* There
is as yet no evidence to distinguish urethane and DMBA with respect to the power
of initiating the development of malignant tumours.
SUMMARY.
1. The effects on the dorsal skin of mice of various doses of 2-acetylamino-
fluorene (AAF) , p-dimethylaminoazobenzene (butteryellow, BY), ethyl carbamate
(urethane), methyl bis (fl-chloroethyl) amine hydrochloride (nitrogen mustard,
NM), and NN-di-(2-chloroethyl)-,8-naphthylamine (R48), followed by weekly
applications of 0(5 per cent croton oil in acetone, were studied.
2. Tumour incidence in the urethane group was significantly greater than in
control groups treated with croton oil alone. A few tumours which appeared in
the AAF, BY, and R48 groups were probably due to croton oil. NM gave an
intermediate result of doubtful significance.
3. In a second experiment the effect on mouse skin of urethane, (a) alone,
(b) following treatment with a carcinogen, and (c) followed or accompanied by
treatment with croton oil were studied.
4. Weekly doses of 120 mg. urethane followed by 18 weekly applications of
croton oil produced large numbers of tumours.
5. Altemate applications of 60 mg. urethane and 0 5 per cent croton oil at
3-4 days' intervals had a similar effect.
6. Urethane alone, either as 2 weekly applications of 120 mg. or as 18 weekly
applications of 60 mg., produced no tumours.
7. 18 weekly applications of 60 mg. urethane following an initial application
of0 3 mg. 9: 10-dimethyl -1: 2-benzanthracene (DMBA) produced no tumours.
8. Urethane produced no recognisable histological changes in mouse skin,
even after prolonged application.
9. Tumours produced by urethane in conjunction with croton oil had the
appearance of benign papillomata. It is pointed out that, by analogy with the
effect of DMBA followed by croton oil, malignant tumours are not to be expected
till a later date.*
10. The relation between the effective initiating doses of DMBA and urethane
respectively is discussed.
11. It is concluded that urethane is an initiator of carcinogenesis, but not a
carcinogen or a co-carcinogen, for mouse skin.
Addendum.-After this work was completed our attention was drawn to a
recent report by Graafi, Vlamynch, Hoffman and Schulz (1953). The authors
have tested the effects on mouse skin of various substances applied alternately
with croton oil for periods up to 12 months. 1: 2-Benzanthracene, and urethane,
applied in this way, produced a significantly greater number of tumours than
croton oil alone. They were much fewer in number, and occurred a good deal
later, than those in our urethane groups, reaching a maximum of 18 in 9 surviv-
ing mice in the 1: 2-benzanthracene group and 12 in 19 surviving mice in the
* A mouse of Group 13, which had received alternate urethane and croton oil applications for
18 weeks, developed a malignant tumour about the middle of the treated area, 8 weeks after the end
oftreatment. Microscopically, this was seen to be a squamous epithelioma penetrating the panniculus
carnosus, and there was a metastasis in the left axillary gland.
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urethane group at 12 months. One malignant tumour occurred in their urethane
group 6 months after the end of treatment. Pyrene, phenanthrene, acenaph-
thene, fluorene, aminofluorene, acetylaminofluorene, butter yellow, 3' methyl
butter yellow, and camphor, produced either no tumours, or so few that they
might have been due to the croton oil.
With respect to the substances also tested by us (urethane, acetylamino-
fluorene, and butter yellow) our results confirm theirs.
We are indebted to Miss E. Firth, B.Sc., for skilled technical assistance.
The expenses of this research were partly defrayed ouit of a Block Grant fromi
the British Empire Canicer Campaign.
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